Engineering virus resistance via CRISPR-Cas systems.

In prokaryotes, CRISPR/Cas adaptive immunity systems target and destroy nucleic acids derived from invading bacteriophages and other foreign genetic elements. In eukaryotes, the native function of these systems has been exploited to combat viruses in mammals and plants. Rewired CRISPR/Cas9 and CRISPR/Cas13 systems have been used to confer resistance against DNA and RNA viruses, respectively. Here, we discuss recent approaches employing CRISPR/Cas systems to combat viruses in eukaryotes, highlight key challenges, and provide future perspectives. Moreover, we discuss the application of CRISPR/Cas systems in genome-wide screens to identify key host factors for virus infection to enhance our understanding of basic virus biology and to identify and study virus-host interactions.

[1]  T. Ried,et al.  Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability , 2014, Genome research.

[2]  Gaelen T. Hess,et al.  Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes. , 2017, Molecular cell.

[3]  Fan Yang,et al.  RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection , 2014, Proceedings of the National Academy of Sciences.

[4]  M. Mahfouz,et al.  Engineering resistance against Tomato yellow leaf curl virus via the CRISPR/Cas9 system in tomato , 2017, bioRxiv.

[5]  R. Bundschuh,et al.  Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9 , 2016, Scientific Reports.

[6]  R. Aman,et al.  CRISPR-Cas13d mediates robust RNA virus interference in plants , 2019, Genome Biology.

[7]  A. Regev,et al.  Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System , 2015, Cell.

[8]  Cheng Lu,et al.  Construction of a One-Vector Multiplex CRISPR/Cas9 Editing System to Inhibit Nucleopolyhedrovirus Replication in Silkworms , 2019, Virologica Sinica.

[9]  Louis Flamand,et al.  Herpesviruses and Chromosomal Integration , 2010, Journal of Virology.

[10]  Aiming Wang.  Dissecting the molecular network of virus-plant interactions: the complex roles of host factors. , 2015, Annual review of phytopathology.

[11]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[12]  J. Fu,et al.  Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus , 2015, Gene Therapy.

[13]  K. Khalili,et al.  The CRISPR/Cas9 genome editing methodology as a weapon against human viruses. , 2015, Discovery medicine.

[14]  Max J. Kellner,et al.  RNA editing with CRISPR-Cas13 , 2017, Science.

[15]  C. Rice,et al.  Getting Rid of a Persistent Troublemaker to Cure Hepatitis , 2014, Science.

[16]  Rodolphe Barrangou,et al.  CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. , 2014, Molecular cell.

[17]  S. Sehrawat,et al.  Immunity and immunopathology to viruses: what decides the outcome? , 2010, Nature Reviews Immunology.

[18]  Joel D. Baines,et al.  Herpesviruses remodel host membranes for virus egress , 2011, Nature Reviews Microbiology.

[19]  S. Konermann,et al.  Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors , 2018, Cell.

[20]  P. Stern,et al.  Opportunities and challenges for human papillomavirus vaccination in cancer , 2018, Nature Reviews Cancer.

[21]  Keiichiro Suzuki,et al.  Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells , 2015, Nature Communications.

[22]  O. Dong,et al.  Genetic Engineering for Disease Resistance in Plants: Recent Progress and Future Perspectives1[OPEN] , 2019, Plant Physiology.

[23]  Engineering resistance against Tomato yellow leaf curl virus via the CRISPR/Cas9 system in tomato , 2017, bioRxiv.

[24]  M. Mahfouz,et al.  Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation. , 2017, Biotechnology advances.

[25]  H. zur Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature reviews. Cancer.

[26]  M. Mahfouz,et al.  CRISPR/Cas9-mediated viral interference in plants , 2015, Genome Biology.

[27]  Kira S. Makarova,et al.  Diversity and evolution of class 2 CRISPR–Cas systems , 2017, Nature Reviews Microbiology.

[28]  P. Gendron,et al.  CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. , 2016, Cell reports.

[29]  Yu Chen,et al.  Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection , 2015, Scientific Reports.

[30]  E. Charpentier,et al.  Adaptation in CRISPR-Cas Systems. , 2016, Molecular cell.

[31]  H. Czosnek,et al.  A worldwide survey of tomato yellow leaf curl viruses , 1997, Archives of Virology.

[32]  A. Grakoui,et al.  Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. , 2016, Trends in microbiology.

[33]  D. Margolis,et al.  Eradicating HIV-1 infection: seeking to clear a persistent pathogen , 2014, Nature Reviews Microbiology.

[34]  Di Zhang,et al.  CCR5 Gene Disruption via Lentiviral Vectors Expressing Cas9 and Single Guided RNA Renders Cells Resistant to HIV-1 Infection , 2014, PloS one.

[35]  Guohui Zhou,et al.  Engineering plant virus resistance: from RNA silencing to genome editing strategies , 2019, Plant biotechnology journal.

[36]  J. Daròs,et al.  Multi‐targeting of viral RNAs with synthetic trans‐acting small interfering RNAs enhances plant antiviral resistance , 2019, The Plant journal : for cell and molecular biology.

[37]  Yoshimitsu Takahashi,et al.  In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. , 2014, Biochemical and biophysical research communications.

[38]  C. Seeger,et al.  Targeting Hepatitis B Virus With CRISPR/Cas9 , 2014, Molecular therapy. Nucleic acids.

[39]  J. Karn,et al.  Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing , 2015, Scientific Reports.

[40]  Eugene V Koonin,et al.  Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. , 2015, Molecular cell.

[41]  R. Hotchkiss,et al.  Host-directed therapies for bacterial and viral infections , 2017, Nature Reviews Drug Discovery.

[42]  Yoshio Koyanagi,et al.  Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus , 2013, Scientific Reports.

[43]  Ben Berkhout,et al.  CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  Bryan R. Cullen,et al.  Inactivation of the Human Papillomavirus E6 or E7 Gene in Cervical Carcinoma Cells by Using a Bacterial CRISPR/Cas RNA-Guided Endonuclease , 2014, Journal of Virology.

[45]  Aviv Regev,et al.  RNA targeting with CRISPR–Cas13 , 2017, Nature.

[46]  M. Mahfouz,et al.  CRISPR/Cas9-Mediated Immunity to Geminiviruses: Differential Interference and Evasion , 2016, Scientific Reports.

[47]  Ahmed Mahas,et al.  RNA virus interference via CRISPR/Cas13a system in plants , 2017, Genome Biology.

[48]  M. Nassal.  HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B , 2015, Gut.

[49]  Eric S. Lander,et al.  C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector , 2016, Science.

[50]  Yongzeng Wang,et al.  Roles for host factors in plant viral pathogenicity. , 2004, Current opinion in plant biology.

[51]  Luciano A. Marraffini,et al.  CRISPR-Cas immunity in prokaryotes , 2015, Nature.

[52]  Guohui Zhou,et al.  Establishing RNA virus resistance in plants by harnessing CRISPR immune system , 2018, Plant biotechnology journal.

[53]  Cary A Moody,et al.  Human papillomavirus oncoproteins: pathways to transformation , 2010, Nature Reviews Cancer.

[54]  R. Shattock,et al.  Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. , 2015, The Journal of general virology.

[55]  Chunsheng Dong,et al.  Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. , 2015, Antiviral research.

[56]  David S. Weiss,et al.  Cas9-mediated targeting of viral RNA in eukaryotic cells , 2015, Proceedings of the National Academy of Sciences.

[57]  D. Dryden,et al.  The biology of restriction and anti-restriction. , 2005, Current opinion in microbiology.

[58]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[59]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[60]  M. Martin,et al.  Molecular organization of the AIDS retrovirus , 1985, Cell.

[61]  Sita J. Saunders,et al.  An updated evolutionary classification of CRISPR–Cas systems , 2015, Nature Reviews Microbiology.

[62]  Sylvain Moineau,et al.  Bacteriophage resistance mechanisms , 2010, Nature Reviews Microbiology.

[63]  T. Mogensen.  Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses , 2009, Clinical Microbiology Reviews.

[64]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[65]  Takanori Nakane,et al.  Structure and Engineering of Francisella novicida Cas9 , 2016, Cell.

[66]  Stan J. J. Brouns,et al.  Evolution and classification of the CRISPR–Cas systems , 2011, Nature Reviews Microbiology.

[67]  M. Jahn,et al.  Genetics of plant virus resistance. , 2005, Annual review of phytopathology.